At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DPP-4 Inhibition With Sitagliptin and the Risk for Hypoglycaemia in the Fasting State in Subjects With Type 2 Diabetes Treated to Fasting Plasma Glucose Targets With Insulin Glargine and Metformin
In Brief
A Phase 2 clinical trial evaluating Sitagliptin 100 mg and Placebo for Pharmacological Action. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic episodes, and/or ameliorating the severity of hypoglycemic episodes in the case that they should occur. The endpoints have defined such that consequences of this hypothesis can be measured.
Study Details
Timeline
Interventions
The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.
The treatment consists of placebo tablets for up to 24 weeks.